Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?

Michelle N. Rheault, William E. Smoyer

Research output: Contribution to journalComment/debatepeer-review


Gross et al. present results of the EARLY PRO-TECT trial, a randomized controlled trial of ramipril versus placebo in children with early-stage Alport syndrome. Although under-enrolled and not a positive trial in the traditional sense, EARLY PRO-TECT does provide strong supportive evidence for both long-term safety and a clinical benefit of early treatment with angiotensin-converting enzyme inhibitors in slowing the progression of both albuminuria and estimated glomerular filtration rate decline in children with Alport syndrome.

Original languageEnglish (US)
Pages (from-to)1104-1106
Number of pages3
JournalKidney international
Issue number6
StatePublished - Jun 2020

Bibliographical note

Publisher Copyright:
© 2020 International Society of Nephrology

Copyright 2020 Elsevier B.V., All rights reserved.

PubMed: MeSH publication types

  • Journal Article

Fingerprint Dive into the research topics of 'Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?'. Together they form a unique fingerprint.

Cite this